Mifepristone

Mifepristone is a synthetic progesterone antagonist, related to norethindrone. Chemically Mifepristone is identified as (11β,17β)-11-[ 4-(dimethylaminoamino) phenyl ]-17-hydroxy-17-(1-propynyl) estra-4, 9-dien-3-one. Mifepristone is used orally for termination of pregnancy up to 9 weeks gestation.it should be used only in centres licensed under the abortion act. If abortion is not complete after 36-48 hrs, treatment with gemeprost should be given surgical abortionmay be used if drug treatment fails.

Brands
Adult Dose
Dose: 12 mg/kg
Single Dose: 12 (12)
Frequency: As recommended.
Route: PO
Instructions: Once
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
. It is of Synthetic origin and belongs to Norethisterone. It belongs to Progesterone antagonist pharmacological group on the basis of mechanism of action and also classified in Abortifacients pharmacological group.The Molecular Weight of Mifepristone is 429.60. Its pKa is 3.7.
Contraindications
Mifepristone
Effects
The severe or irreversible adverse effects of Mifepristone, which give rise to further complications include Hypotension, Hypotension, Hypersensitivity reactions.The symptomatic adverse reactions produced by Mifepristone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fever, Chills, Malaise, Heavy bleeding, dizziness, Urtercaria, GI craps.
Indications
'Mifepristone is primarily indicated in conditions like Abortion, Contraception, Cushing''s syndrome, Hypothyroid coma, Induction of labour, Menstruation disorders, Muscle spasm of varied aeitology, Routine management of the 3rd stage of labour, Severe nausea and vomiting (prevention), Softening and dilatation of cervix before mechanical cervical dilatation, Termination of pregnancy of 13-24 weeks gestation.'
Interactions
Mifepristone is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAspirinDeflazacortErgometrine (Maleate)Oral contraceptive increase platelet aggregability and promote thrombus formationModeratesimultaneous use of ergometrine with oral contraceptives should be avoidedGemeprostTenoxicamTenoxicam should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
SGPT level disturbance. Hematocrit Value Changes in alkaline phosphatase activity
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store in a well closed container, at room temperature.
Warnings
Mifepristone should not be given to patients with chronic adrenal failure, haemorrhagic disorders or those receiving anticoagulants or long term corticosteroid therapy, impaired liver or kidney function. It should be used with caution in patients with chronic obstructive air way disease, asthma or cardiovascular disease. It is not recommended to use during pregnancy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.